New combo attack on prostate cancer: drug, surgery, and radiation
NCT ID NCT07490210
First seen Mar 25, 2026 · Last updated May 06, 2026 · Updated 5 times
Summary
This study tests whether adding surgery and radiation to a new hormone drug (rezvilutamide) helps men whose prostate cancer has spread to a few spots (oligometastatic). About 300 men will be split into three groups: one gets the drug alone, another gets the drug plus surgery, and the third gets the drug plus surgery and radiation. The goal is to see which approach delays cancer growth the longest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.